Replies to post #302122 on Anavex Life Sciences Corp (AVXL)

[infitvest]

Its a SAVA pump article with very little data. All data from phase 2 that's been talked about except now that poster is adding on his own wild speculations (approval in 2022 says it all... that individual can't do math either b/c the timeline is impossible based on A). Not recruiting yet and B). Length of trials being completed)

My favorite part is below, and this is the clear difference between Remi and Missling. Missling is going to have his name remembered for making a positive impact in patients lives. Remi will be known as the guy who worked tirelessly for a decade trying to figure out ANY drug for someone in big pharma to buy. Remi does not care if his drug helps anyone, he cares to get a buyout so he can finally retire from a decade of being unsuccessful.

Remi is looking to hand over an AD drug for quick $$$ and to get out of the scene. Why do you think Missling was interviewed by NIH regarding success stories with patients and NOT Remi? .

Buyout
We think simufilam will receive BTD sometime soon, and be approved sometime next year. But we don't think it will be Cassava Sciences that gets the drug across the finish line. The CEO from the Facebook interview (46:00):

We probably will hand this drug over to someone who has all the infrastructure in place, who specializes in distribution and getting the drug from the warehouse to the patient.

And for quite a price tag we think. As we have said, this drug compares quite favorably to Lilly's donanemab, and the AD market is enormous, growing, and bereft of disease-modifying treatments. It is not hard to translate the value of a drug like simufilam to $45 billion in market cap, which puts the stock at $1,125 per share.

[Amatuer17]

Like A2-73, it is a long journey.
2 large trials - results will be Q4-2023 or Q1-2024 at earliest.
Good thing is - they have raised good amount of money and may get BTD due to 100% response rate in P2. Seems they have good contacts in right places to get visibility.

“Cassava will run two concurrent placebo-controlled Phase 3 trials beginning in the second half of 2021. The first is approximately 1,000 patients and set to last 18 months and begin in Q3, the second is approximately 600 patients for 9-12 months and begins in Q4.”